ArticleNPJ precision oncology2026
Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Intestinal Obstruction Caused by Dual-Component Metastasis From Combined Small Cell Lung Cancer: A Rare Case and Literature Review.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Small cell lung cancer (SCLC) is a highly aggressive malignancy with strong associations to smoking, characterized by initial platinum sensitivity followed by rapid recurrence and poor long-term survival. The evolutionary processes driving this high plasticity and intratumoral heterogeneity remain inadequately understood, hampering the development of effective therapies. In this study, we established a comprehensive spatial transcriptomic (ST) landscape of SCLC. Our approach integrated two key methodological innovations: the Edgeindex metric for the quantitative assessment of tumor spatial architecture, and a specialized artificial neural network (ANN) model for precise tumor annotation. Utilizing this analytical framework, we systematically resolved SCLC heterogeneity across clinical, spatial, functional, and temporal dimensions. Furthermore, pathway enrichment analysis was performed to explore the underlying molecular mechanisms. This work provides a multi-dimensional resource for deciphering the complexity of SCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.